FDA Downgrades Fibromyalgia Therapy Device to Class II
Published Date: 6/26/2026
Rule
Summary
The FDA is officially classifying a computerized behavioral therapy device for fibromyalgia symptoms as a Class II device, meaning it meets safety and effectiveness standards with special controls. This change helps patients get easier access to this innovative treatment by reducing some regulatory hurdles. The new classification is effective June 26, 2026, and could speed up how quickly these devices reach the market without extra costs.
Analyzed Economic Effects
5 provisions identified: 2 benefits, 2 costs, 1 mixed.
Device Reclassified to Class II — Easier Access
The FDA officially classified the computerized behavioral therapy device for treatment of fibromyalgia symptoms as Class II with special controls, effective June 26, 2026 (classification applicable May 9, 2023). The FDA says this classification will provide reasonable assurance of safety and effectiveness and will enhance patients' access by reducing regulatory burdens.
510(k) Premarket Notification Is Required
FDA states that computerized behavioral therapy devices for fibromyalgia symptoms are subject to premarket notification requirements under section 510(k) of the FD&C Act (they have not been exempted under section 510(m)). Manufacturers must therefore submit a 510(k) to market these Class II devices.
New Special Controls: Clinical Data, Software, Labeling
FDA set special controls for this device type: clinical data must evaluate improvement in fibromyalgia symptoms and relevant adverse events; software verification, validation, and hazard analysis are required; and physician and patient labeling must include recommended treatment regimes (frequency and duration) and a summary of clinical data including adverse events.
Sets Predicate for Future Devices — Easier 510(k) Route
FDA states that when a device is classified into class II through the De Novo process, that device can serve as a predicate for future devices of that type, allowing other sponsors to use the less burdensome 510(k) process instead of a De Novo or PMA. This can reduce regulatory burdens for future device sponsors.
Prescription-Only Requirement Maintained
At the time of classification, the computerized behavioral therapy device for fibromyalgia symptoms is a prescription device intended to provide a computerized version of behavioral therapy. Prescription devices remain subject to prescription-only conditions and related labeling rules.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-19704, Robotically-Assisted Surgical Devices-Premarket Submissions; Draft Guidance for Industry and Food and Drug Administration Staff; Availability
The FDA just dropped a draft guide for companies making robot-assisted surgical devices, showing how to get their products approved before selling. If you’re in the biz, now’s the time to check it out and send your feedback by November 24, 2026. This guide aims to make the approval process clearer and smoother, potentially saving time and money down the road.
2026-19655, Jeffrey Thies: Final Debarment Order
Jeffrey Thies is banned for 10 years from importing any drugs into the U.S. because he was convicted of trafficking fake drugs. He didn’t respond to the FDA’s notice, so the ban started on September 25, 2026. He can apply to end the ban anytime, but until then, no drug imports for him!
Previous / Next Documents
Previous: 2026-12900, Medical Devices; Clinical Chemistry and Toxicology Devices; Classification of the Prognostic Test for Development or Progression of Preeclampsia
The FDA is officially putting the test that predicts preeclampsia risk into a safer, easier-to-get category called Class II. This change helps make sure the test works well and is safe, while also making it simpler for patients to access this important health tool. The new rules took effect on June 26, 2026, but the classification has been in place since May 18, 2023, helping companies save time and money on approvals.
Next: 2026-12902, Medical Devices; Immunology and Microbiology Devices; Classification of the SARS-CoV-2 Serology Test
The FDA is officially putting the COVID-19 antibody (serology) test into a safer, easier-to-manage category called Class II, starting June 26, 2026. This change helps make sure the tests work well and are safe, while also making it simpler for companies to bring new and better tests to patients. If you’re a test maker or user, expect smoother rules and better access without extra costs or delays.